Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Clinical development of targeted and immune based anti-cancer therapies

Fig. 1

Mechanism of action of anti-EGFR drugs. The activation of EGFR has been implicated in the development of several cancers. There are three generations of tyrosine kinase inhibitors that target the tyrosine kinase of EGFR. Recently the monoclonal antibodies, cetuximab, panitumumab and necitumumab, were developed to target EGFR and thereby prevent the downstream signaling resulting in the proliferation and survival of cancer cells

Back to article page